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Summary One hundred large bowel carcinomas operated on between 1978 and 1982 were studied
immunohistochemically with regard to expression of HLA-DR antigens. Three sections from each tumour
were investigated by a semiquantitative scoring system, and a mean score for each patient established. Based
on this scoring system, the tumours were divided into three groups: 0; 0.1-1.0; and > 1.0. All patients were
followed until death (n = 68) or until June 1, 1992, and all cancer-specific deaths (n = 56) have been recorded.
Analysis of survival in the whole patient group showed significant difference between the three levels of
tumour HLA-DR expression (P = 0.006); patients who had tumours with strong HLA-DR expression showing
the best survival. In a stratified analysis after Dukes' stages there was still a significant difference (P>0.001)
between the three levels of HLA-DR staining intensity. After a multiple regression analysis (Cox) with
correction for different variables, the HLA-DR expression maintained its significance as a risk factor. To our
knowledge this is the first time a relationship between intensity of tumour DR expression and survival has
been shown in large bowel carcinoma.
Several attempts have been made to define histopathological
characteristics of prognostic significance for patients with
large bowel carcinoma. A positive correlation between histo-
logical tumour grade and survival time has been reported
(Remmele & Heine, 1981), but up to now, staging has been
considered the most reliable way to assess prognosis (Dukes
& Bussey, 1958; Turnbull et al., 1967; Remmele & Heine,
1981). The preoperative plasma CEA level has proved
valuable in follow-up studies after surgery for large bowel
carcinomas (Wanebo et al., 1978; Rognum, 1986; Meling et
al., 1992). During the last years several papers applying flow
cytometric DNA determination methods in human solid
tumours have been published, and studies have shown that
the presence of distinctly aneuploid DNA ploidy pattern in
large bowel carcinoma worsens survival rates significantly
(Wolley et al., 1982; Rognum et al., 1987a, 1991).
HLA class II antigen expression has recently been related
to good prognosis in squamous cell carcinoma of the larynx
(Esteban et al., 1990) and breast carcinoma (Concha et al.,
1991), whereas HLA-DR positivity was related to a bad
prognosis in malignant melanoma (Zaloudik et al., 1988). In
large bowel carcinomas the association between HLA-DR
expression and prognosis is less clear, since Gutierrez et al.
(1987) found a correlation between DR-expression and prog-
nosis according to Jass's stages (Jass et al., 1986), while
M6ller et al. (1991) did not find any influence of HLA-DR
on disease-free survival.
The purpose of the present study was to test a possible
prognostic significance of tumour DR-expression in 100 large
bowel carcinomas with at least 10 years postoperative obser-
vation time.
Patients, materials and methods
Patients
One hundred large bowel carcinomas from 100 patients
operated on between 1978 and 1982 were studied immunohis-
tochemically with regard to expression of HLA-DR antigens.
The mean age of the patients was 64.5 years (range 28 to 89
years), and there were 52 men and 48 women. All tumours
were staged according to the extended Dukes' scheme, which
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in addition to Dukes' stages A, B, and C, ascribed stage D to
tumours with distant organ metastases and inoperable
tumours (Turnbull et al., 1967). The tumours were in addi-
tion graded as well-, moderately-, or poorly differentiated
(Ashley, 1978). Gross pathological examination was per-
formed by the same observer (T.O.R.) throughout the study.
The distribution of the variables is given in Table I.
Immunohistochemistry
Tissue slices from each tumour were fixed in cold 96%
ethanol and processed for paraffin embedding as described
previously (Brandtzaeg, 1974). Sections cut at 6gm were
dewaxed and subjected to immunofluorescence staining at
room temperature. One section from each series was stained
by a trichrome routine method (HAS) containing haematox-
ylin, azofloxin and saffron (Stave & Brantzaeg, 1977).
A murine monoclonal antibody to a nonpolymorphic
human HLA-DR antigen (Beckton Dickinson, Sunnyvale,
Calif., USA) was applied (1:20 for 20h) in an indirect 3-step
immunofluorescence method (Brandtzaeg & Rognum, 1983),
including affinity purified biotinylated horse anti-mouse IgG
(0.05gIgGl-', 3 h) and fluorescein isothiocyanate (FITC)-
labelled avidin (0.05 gl1', 30min), both purchased from
Vector Laboratories (Burlingame, Calif., USA). The horse
reagent was absorbed with normal human serum to avoid
interspecies cross-reactions.
To test the specificity of the staining procedure, the
primary antibody was omitted in adjacent sections from a
DR-positive tumour.
To test the specificity of the primary antibody, an adjacent
section from a DR-positive tumour was stained with a
monoclonal antibody of the same isotype, but without
specificity relevant for colon tissue (monoclonal antibody
against a neoepitope on the complement factor C9; Mollnes
et al., 1985).
Observations were done in a Leitz Aristoplan fluorescence
microscope equipped with an Osram Hg 100 W lamp for
fluorescein (green emission). Narrowband excitation and
selective filtration of the fluorescence colour were obtained
with a Ploem-type epi-illuminator. In 97 of the 100 tumours,
three different blocks of tumour tissue were evaluated - one
from the centre of the tumour and two from the periphery -
while in the last three tumours we only had 2, 2 and 1 block,
respectively. Both the tumour and the transitional mucosa
were evaluated. The epithelial staining for HLA-DR antigens
were scored semiquantitatively on arbitrary scales from 0 to
3. HLA-DR+ cells showed usually diffuse distribution of
such determinants throughout the cytoplasm with peripheral
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Table I Clinicopathologic characteristics of the patients
100 Number of patients
Sex
Male
Female
Mean age (yr)
Range
Mean follow-up (yr)
Range
Dukes' stage
A
B
C
D
Histological grade
Well differentiated
Moderately differentiated
Poorly differentiated
Localisation
Right colon
Left colon
Rectum
52
48
64.5
28-89
11.4
10-14.3
20
36
25
19
11
70
19
32
25
43
intensification, particularly apically in glandular structures.
Both staining intensity and distribution area of staining were
taken into account, each contributing about 50% of the sum.
A score of 0 was given for virtually no staining: and 3 for
intense overall fluorescence. 'Tumour score' was the mean
score of all blocks from each tumour. The same investigator
(S.N.A.) was responsible for the fluorescence scoring
throughout the study; a blind test for both intra- and inter-
observer reproducibility was performed. For the inter-
observer test new sections were cut and immunostained.
Proportions of agreement (P.) and Kappa values were
estimated in the analysis of observer variability (Landis &
Koch, 1977).
The distribution of the DR was, in addition, separately
categorised as heterogenous (extensive, intermediate or slight)
or homogenous. An extensive degree of heterogenous stain-
ing refers to the presence of abrupt transition between
positive and negative epithelium within the same crypt (Rog-
num et al., 1983).
a
b
Figure 1 Moderately differentiated large bowel carcinoma. a, HAS staining (magnification x 20). b, Adjacent section stained green
for HLA-DR determinants (magnification x 80).82 S. NORHEIM ANDERSEN etal.
Calculation ofsurvival rates
All patients were followed until death or until June 1, 1992,
with a mean of 11.4 years (range 10 to 14.3 years). Survival
rates were computed by the actuarial or life-table method.
Crude survival was based on all deaths; for corrected survival
rates, deaths not due to cancer were censored at time of
death. Information about recurrences and deaths due to
cancer was obtained from the hospital records or the post-
mortem reports. The log-rank procedure was used to assess
the statistical significance between survival distribution.
To estimate the effect of different factors on survival, a
multivariate analysis was done by the proportional-hazards
method proposed by Cox (1972). Included in the analysis
were the following factors: age, sex, clinicopathological stage,
histologic grade, DNA ploidy pattern, DR staining,
preoperative CEA plasma level, and tumour site.
Results
HLA-DR stainingpattern, Dukes' stage, andhistological grade
When omitting the primary antibody or replacing it with an
antibody of the same isotype (IgG2a), no staining was seen
in adjacent sections from a tumour which stained positive
with the anti-HLA-DR antibody.
Based on three samples, 52 tumours showed HLA-DR
positivity in varying degrees (Figure 1) and 48 were negative.
There was some degree of intratumour variation; when
evaluating only one section from each specimen, 38 were
positive and 62 negative. Consequently, a mean score for
each tumour was based upon the average of the scores from
the three sections. The tumours were then divided into three
groups according to the mean score: 0; 0.1-1.0; and
>1.0.
There were no significant differences in HLA-DR score
between tumours in each Dukes' stage (Table II), whereas
there were slightly more DR-positive tumours in the poorly
differentiated group, compared to the better differentiated
tumours (P = 0.04), (Table III).
Concerning the heterogeneity of HLA-DR staining in the
tumour, 39 of the tumours showed variable staining through-
out the tumour tissue, whereas 61 showed a homogenous
staining pattern, either positive (13) or negative (48). No
difference in degree of heterogeneity was observed with
regard to Dukes' stage, while there was a tendency for poorly
differentiated carcinomas to be more homogenously stained
(P = 0.04).
Intraobserver reproducibility was 'substantial' (Kap-
pa = 0.61) and interobserver (including repeated sectioning
Table II HLA-DR expression according to Dukes' stages in
colorectal carcinoma patients
Dukes' HLA-DR expression
stage 0 0.1-1.0 > 1.0 Total
A 9 10 1 20
B 17 13 5 35
C 8 13 5 26
D 14 4 1 19
Total 48 40 12 100
Chi square = 10.01; d.f. 6; P = 0.12.
and staining) reproducibility was 'moderate' (Kappa = 0.46)
(Figure 2), according to the classification by Landis and
Koch (1977).
Tumour HLA-DR expression and survival analysis
During the follow-up period there were 56 cancer specific
deaths, whereas 12 patients died from other causes. Analysis
of survival in the whole patient group showed significant
differences between the three levels of tumour HLA-DR
expression: 0; 0.1-1.0; > 1.0 (X2 = 10.214, d.f. = 2, P = 0.006),
(Figure 3). In a stratified analysis after Dukes' stages, there
was still a significant difference (P<0.001) between the three
levels of HLA-DR staining intensity (Figure 4).
Only one patient with tumour score for HLA-DR above
1.6 died from his cancer. This 73 year-old male patient,
operated on for a rectal carcinoma, Dukes' stage B, survived
for 6.8 years. Another male patient with a poorly
differentiated Dukes'stage D rectal tumour with a HLA-DR
score of 1.5, survived for 2.8 years.
According to the multivariate analysis, adjustment for
other risk factors did not essentially change the estimate of
the prognostic effect of HLA-DR expression on the relative
risk for death from large bowel carcinoma (Table IV).
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Table III HLA-DR expression according to histological grade
Histological HLA-DR expression
grade 0 0.1-1.0 > 1.0 Total
Well 5 6 0 11
Moderately 35 29 6 70
Poorly 8 5 6 19
Total 48 40 12 100
Chi square = 9.79; d.f. 4; P = 0.04.
2
HLA-DR SCORE
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Figure 2 Scatter diagrams of interobserver and intra-observer
reproducibility. The degree of accordance for HLA-DR score a,
between the first observation by SNA and the second one by
TOR after new slicing and staining (Po= 0.63 (17/27) Kappa
0.46), and b, between two observations by the same observer
(SNA), the last performed blindly after 12 weeks (PO = 0.7 (14/20)
Kappa 0.61).
~ ~ ~ ~
1HLA-DR, LARGE BOWEL CANCER, AND SURVIVAL 83
Discussion
The main finding of the present paper was the significant
relationship between the HLA-DR expression of the tumour
cells and survival of the patients. To our knowledge this is
the first report of such a relationship, and it was surprising,
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Figure 3 Survival curves (corrected for deaths not due to cancer)
for patients with different degrees of HLA-DR expression, as
evaluated by immunohistochemical scoring. The patients are
divided into three groups, according to the staining intensity.
Interval of the semiquantitative scores are given by different types
of lines in the figure; patients whose tumours have no HLA-DR
expression ( ~); weak DR expression, 0.1I-1I.0 (....); and
strong DR expression, > 1.0 ( ---). The difference between the
three levels is statistically significant (P = 0.006).
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since we (like Ghosh et at., 1986), were unable to demon-
strate association between HLA-DR expression and Dukes'
stage.
Under normal conditions colonic mucosa does not express
HLA class II molecules (Daar et at., 1982; 1984; Rognum et
at., 1987b), but in pathological conditions - inflammation,
dysplasia, carcinoma - the epithelium may express varying
amounts of these antigens (Rognum et at., 1983; 1987b;
Ruiz-Cabello et at., 1988).
M6ller et at. (1991) evaluated expression of HLA-A, B, C,
and HLA-DR molecules, invariate chain, and LFA-3 (CD
58) in colorectal carcinoma, and their impact on tumour
recurrence. The follow-up ranged from 65 to 45 months.
They found that an induction of HLA-DR molecules was
seen in 55% of the tumours, but the presence was not
correlated with the recurrence rate. However, the authors
Table IV Relative risk RR (proportional hazard) with 95%
confidence interval (95% CI) for death from colo-rectal cancer ac-
cording to different risk factors
Variable RR 95% CI
Adjusted for age and sex:
HLA-DR weakexpression vs none 0.63 (0.36-1.09)
HLA-DRstrongexpression vs none 0.16 (0.04-0.65)
Adjusteda
HLA-DR weakexpression vs none 0.80 (0.40-1.59)
HLA-DR strongexpression vs none 0.12 (0.02-0.61)
Dukes' stage D vsA 35.37 (10.71-116.81)
Dukes' stage C vs A 7.03 (2.63-18.82)
Dukes' stage B vsA 1.69 (0.64-4.47)
Rectum vscolon 1.89 (1.03-3.49)
Diploid vsaneuploid 0.80 (0.40-1.62)
Pre-operative CEA pr. 10 jig l` 1.19 (1.05-1.33)
Histologicalgrade, 1.13 (0.48-2.67)
poorly differentiated vs the rest
aEstimates of relative risk adjusted for age, sex, and mutually for
other variables in the table.
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Figure 4 Survival curves (corrected for death not due to cancer) for patients whose tumours have no HLA-DR expression ( )
weak DR expression, 0.1I-1.0 (.;and strong DR expression, > 1.0 (--;according to Dukes' stages. Stratified P value is less
than 0.001.
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based their calculations on recurrences and not survival time,
and they only judged the immunohistochemical staining to be
either positive or negative. Furthermore, they applied a stan-
dard indirect immunoperoxidase method, whereas we used an
indirect immunofluorescence technique. The latter method
may perhaps make it easier to distinguish between different
degrees of staining intensity, though the advantages of
immunofluorescence techniques over immunoperoxidase has
not been proven in quantitative evaluation of antigens in
artificial tissue blocks (Valnes et al., 1984). We are now
comparing the alkaline phosphatase anti-alkaline phos-
phatase (APAAP) technique with the immunofluorescence
method in a blind study.
In the present study, with a follow-up period of 10-14
years, 52% of the tumours showed positive staining for
HLA-DR antigens in varying degrees. This is in agreement
with previous studies which report detectable staining in
about half of all colon carcinomas (Gutierrez et al., 1987;
Degener et al., 1988; Ruiz-Cabello et al., 1988; Moller et al.,
1991).
In 39% of the tumours heterogenous staining was found,
which is in accordance with Daar & Fabre (1983).
Heterogenous staining of HLA-DR in large bowel car-
cinomas has been claimed to be more common in well
differentiated tumours, while the antigen expression becomes
more homogeneous with decreasing degrees of differentiation
(Rognum et al., 1983). This would be in agreement with the
clonal proliferation theory of tumour development proposed
by Nowell (1976). In the present study we could not find any
relationship between heterogeneity and Dukes' stage. How-
ever, poorly differentiated tumours tend to be more often
DR-positive and show a more homogeneous staining pattern.
This finding in part confirms our previous suggestions (Rog-
num et al., 1983).
Because of the significant prognostic impact, we think that
staining for HLA-DR can profitably be included in the
routine diagnostic procedure. Though the operation of scor-
ing is a subjective exercise, our procedure showed good inter-
and intraobserver reproducibility. Patients with negative
tumours should then be followed up more closely and per-
haps receive adjuvant therapy.
Our findings give support to the possibility of immuno-
modulation of tumours. The presence of HLA-DR on the
surface membrane of the tumour cells is a prerequisite for
activation of the CD 4+ T-cells and thereby release of
cytokines, such as tumour necrosis factor-alpha (TNF) and
'y-interferon (INF). Induction of these determinants in
clinically manifest carcinomas might help the patients' own
immune system to inhibit further tumour growth. A human
colonic carcinoma cell line which spontaneously synthesises
surface HLA-DR has in vitro been stimulated to synthesise
surface HLA-DR up to 19-fold when incubated in lym-
phocyte conditioned medium or with recombinant y-inter-
feron (Lampert et al., 1985). In another colonic carcinoma
cell line TNF markedly and synergistically augmented INF-
induced de novo synthesis of HLA-DR molecules (Kvale et
al., 1988), but TNF alone did not induce detectable levels of
DR surface molecules. However, since treatment with TNF
has failed to be of any effect in cancer patients (Rosenberg et
al., 1989), transfection of the TNF gene into tumour-
infiltrating lymphocytes may turn out to be a better approach
also in humans (Rosenberg, 1992). Another possibility might
be manipulation of the tumour cells by gene therapy.
Enhanced expression of class II molecules on tumour cells
can thus be achieved by transfected cytokine genes or by
direct MHC gene transfection (James et al., 1991). Recently a
new gene therapy trial for malignant melanoma, injecting
gene copies encased in liposomes into the tumour, has been
commented on (Hoffman, 1992). Our finding may suggest a
similar approach in large bowel carcinoma by injection of
gene copies into the tumour, encoding HLA-DR deter-
minants which, displayed on the tumour cell surface, might
trigger an immune response.
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